Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases.

A non randomized observation study that is aiming to assess the safety and efficacy of high dose primaquine (1mg/kg per day over 7 days) among patients with intermediate (30-70%) G6PD activity and the safety and efficacy of weekly primaquine among patients who are g6Pd deficient (\<30% activity)

NCT Number	NCT07468513
Lead Sponsor	Menzies School of Health Research Collaborators: Curtin University, University of Melbourne, Arba Minch University, Papua New Guinea Institute of Medical Research, Mahidol Oxford Tropical Medicine Research Unit, Oxford University Clinical Research Unit, Vietnam, Indonesia University
Conditions	Vivax Malaria, G6PD Deficiency
Enrollment	100 participants
Start Date	2024-05-17
Primary Completion	2028-06-30 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-12